Identification of Antipneumococcal Molecules Effective Against Different Streptococcus pneumoniae Serotypes Using a Resazurin-Based High-Throughput Screen
Related Experiment Video
Updated: Feb 26, 2026
Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
Published on: February 24, 2014
Hyung Jun Kim1, Namyoul Kim2, David Shum2
11 Antibacterial Resistance Research Laboratory, Discovery Biology Department, Institut Pasteur Korea , Seongnam-si, Korea.
Abstract:
Streptococcus pneumoniae is a major human pathogen, causing around 1.6 million deaths worldwide each year. By optimizing a resazurin-based assay to detect S. pneumoniae growth in 384-well microplates, we developed a new high-throughput screening (HTS) system for the discovery of antipneumococcal molecules, which was unsuccessful using conventional absorbance measurements. Before applying our protocol to a large-scale screen, we validated the system through a pilot screen targeting about 7,800 bioactive molecules using three different S. pneumoniae serotypes. Primary screenings of a further 27,000 synthetic small molecules facilitated the identification of 3-acyl-2-phenylamino-1,4-dihydropquinolin-4-one (APDQ) derivatives that inhibited growth of S. pneumoniae with MIC90 values <1 μM (0.03-0.81 μM). Five selected APDQ derivatives were also active against Staphylococcus aureus but neither Klebsiella pneumoniae nor Pseudomonas aeruginosa, suggesting that APDQ may act specifically against Gram-positive bacteria. Our results both validated and demonstrated the utility of the resazurin-based HTS system for the identification of new antipneumococcal molecules. Moreover, the identified new antipneumococcal molecules in this study may have potential to be further developed as new antibiotics.
Insights
A new high-throughput screening system using a resazurin assay effectively identified novel antipneumococcal molecules. These compounds show promise as potential new antibiotics against Streptococcus pneumoniae.
Area of Science:
- Microbiology
- Drug Discovery
- Infectious Diseases
Background:
- Streptococcus pneumoniae causes significant global mortality, necessitating new therapeutic strategies.
- Conventional methods for screening antipneumococcal agents have limitations.
- Development of novel antibiotics is crucial to combat drug-resistant bacterial infections.
Purpose of the Study:
- To develop and validate a high-throughput screening (HTS) system for identifying novel antipneumococcal molecules.
- To discover new chemical entities with potent activity against Streptococcus pneumoniae.
- To evaluate the potential of identified compounds as future antibiotic leads.
Main Methods:
- Optimization of a resazurin-based assay for S. pneumoniae growth detection in 384-well microplates.
- Pilot screening of ~7,800 bioactive molecules against three S. pneumoniae serotypes.
- Primary screening of ~27,000 synthetic small molecules to identify growth inhibitors.
Main Results:
- The resazurin-based HTS system successfully identified antipneumococcal molecules, outperforming absorbance measurements.
- Discovery of 3-acyl-2-phenylamino-1,4-dihydropquinolin-4-one (APDQ) derivatives with potent S. pneumoniae inhibition (MIC90 < 1 μM).
- Five APDQ derivatives demonstrated activity against Staphylococcus aureus, indicating potential Gram-positive specificity.
Conclusions:
- The resazurin-based HTS system is validated and effective for discovering new antipneumococcal compounds.
- APDQ derivatives represent a promising new class of potential antibiotics against S. pneumoniae.
- Further development of APDQ derivatives could lead to novel treatments for bacterial infections.
